The current role of systemic chemotherapy in the primary treatment of head and neck cancer

Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review

“…Complete response rates subsequent to induction chemotherapy combined with radiotherapy are usually higher than following radiotherapy alone. In addition to high nodal stage, molecular mechanisms should be identified and integrated in order to elucidate markers of distant metastasis risk (47). The review from Busch et al (47) highlights the recent developments, including randomized trials, comparing radiotherapy and induction chemotherapy, followed by definitive radiotherapy.…”

“…In addition to high nodal stage, molecular mechanisms should be identified and integrated in order to elucidate markers of distant metastasis risk (47). The review from Busch et al (47) highlights the recent developments, including randomized trials, comparing radiotherapy and induction chemotherapy, followed by definitive radiotherapy. The review summarizes the developments in induction chemotherapy, provides critical remarks of recent discoveries and discusses how clinical trials such as those assessing induction chemotherapy should be conducted in the future (46).…”

“…The review summarizes the developments in induction chemotherapy, provides critical remarks of recent discoveries and discusses how clinical trials such as those assessing induction chemotherapy should be conducted in the future (46). There is a requirement for novel perspectives and therapeutic approaches to provide a better understanding and more successful treatment of HNSCC (47). …”

Induction chemotherapy followed by radiochemotherapy for locally advanced head and neck cancer as an individual treatment approach—Feasibility, safety and retrospective survival analysis in twenty‐three patients

“…Currently, cisplatin‐based concurrent chemoradiation (CRT) remains the gold standard for these patients . Induction chemotherapy (ICT) prior to definitive therapy is regarded as an effective approach to shrink locally advanced disease allowing more effective and less toxic therapy, to select patients for organ preservation, to improve radiotherapy effectiveness and also to potentially decrease the risk of distant metastasis due to initial systemic exposure . As no consensus guidelines are available for its use to date, the role of ICT for HNSCC remains controversial despite a number of previously conducted studies.…”

Reposicionamento de fármacos no câncer de boca: Identificação de possíveis agentes

“…(Shah e Gil, 2009). A radioterapia é frequentemente utilizada como tratamento adjuvante bem como agentes quimiotérapicos como a cisplatina, 5-fluorouracil, o cetuximab, docetaxel, entre outros (Busch et al, 2015). Embora tais modalidades terapêuticas adjuvantes e pós-operatórias melhorem o prognóstico da doença, a taxa de mortalidade dos portadores da mesma permanece alta (Belcher et al, 2014).…”